Find Selumetinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 606143-52-6, Azd6244, Arry-142886, Azd 6244, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide, Azd-6244
Molecular Formula
C17H15BrClFN4O3
Molecular Weight
457.7  g/mol
InChI Key
CYOHGALHFOKKQC-UHFFFAOYSA-N
FDA UNII
6UH91I579U

Selumetinib
Selumetinib is an orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.
Selumetinib is a Kinase Inhibitor. The mechanism of action of selumetinib is as a Mitogen-Activated Protein Kinase Kinase 1 Inhibitor, and Mitogen-Activated Protein Kinase Kinase 2 Inhibitor.
1 2D Structure

Selumetinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
2.1.2 InChI
InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
2.1.3 InChI Key
CYOHGALHFOKKQC-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
2.2 Other Identifiers
2.2.1 UNII
6UH91I579U
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Arry 142886

2. Arry-142886

3. Arry142886

4. Azd 6244

5. Azd-6244

6. Azd6244

2.3.2 Depositor-Supplied Synonyms

1. 606143-52-6

2. Azd6244

3. Arry-142886

4. Azd 6244

5. 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide

6. Azd-6244

7. Selumetinib (azd6244)

8. Arry 142886

9. Arry-886

10. Azd6244 (selumetinib)

11. 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide

12. Koselugo

13. 5-(4-bromo-2-chlorophenylamino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide

14. Chembl1614701

15. Chebi:90227

16. 6uh91i579u

17. Nsc741078

18. Ncgc00189073-01

19. Ncgc00189073-02

20. 6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide

21. Dsstox_cid_28870

22. Dsstox_rid_83139

23. Dsstox_gsid_48944

24. 1h-benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-

25. 6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide

26. Azd 6244;5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzo[d]imidazole-6-carboxamide;6-(4-bromo-2-chlorophenylamino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-3h-benzo[d]imidazole-5-carboxamide

27. Cas-606143-52-6

28. Arry142886

29. Selumetinib [usan:inn]

30. Selumetinibum

31. Unii-6uh91i579u

32. 1h-benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-

33. 3ew

34. 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide

35. Selumetinib [mi]

36. Selumetinib [inn]

37. Selumetinib (usan/inn)

38. Selumetinib [usan]

39. Azd6244 - Selumetinib

40. Selumetinib [who-dd]

41. Schembl155456

42. Gtpl5665

43. Selumetinib, Arry-142886

44. Dtxsid3048944

45. Ex-a020

46. Bcpp000367

47. Hms3244g03

48. Hms3244g04

49. Hms3244h03

50. Hms3265k01

51. Hms3265k02

52. Hms3265l01

53. Hms3265l02

54. Hms3654o03

55. Nsc 741o78

56. Bcp01739

57. Tox21_113362

58. Bdbm50355497

59. Mfcd11977472

60. Nsc800882

61. S1008

62. Zinc31773258

63. Akos015904255

64. Tox21_113362_1

65. Bcp9000354

66. Ccg-264774

67. Cs-0059

68. Db11689

69. Ex-8621

70. Nsc-741078

71. Nsc-800882

72. Sb14707

73. Ncgc00189073-07

74. 6-(4-bromo-2-chloro-anilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-benzimidazole-5-carboxamide

75. Ac-25059

76. Am808016

77. Azd6244,selumetinib, Arry-142886

78. Hy-50706

79. Selumetinib (arry142886/azd6244)

80. Azd6244 (selumetinib,arry-142886)

81. Ft-0674552

82. Sw202561-3

83. D09666

84. 143a526

85. Q-101405

86. Q7448840

87. Brd-k57080016-001-01-9

88. 1h-benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-n-(2- Hydroxyethoxy)-1-methyl-

89. 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-1,3-benzodiazole-6-carboxamide

90. 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxy -ethoxy)-amide

91. 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxy-ethoxy)-amide

92. 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid(2-hydroxy-ethoxy)-amide

93. 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxyethoxy)-amide

94. 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid(2-hydroxyethoxy)-amide

95. 6-(4-bromo-2chloro-phenylamino)-7-fluoro-3-methyl-3h-benzoimidazole-5-carboxylic Acid (2-hydroxy-ethoxy)-amide

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 457.7 g/mol
Molecular Formula C17H15BrClFN4O3
XLogP33.6
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass456.00001 g/mol
Monoisotopic Mass456.00001 g/mol
Topological Polar Surface Area88.4 Ų
Heavy Atom Count27
Formal Charge0
Complexity523
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients 2 years who have symptomatic, inoperable plexiform neurofibromas (PN).


FDA Label


Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above


5 Pharmacology and Biochemistry
5.1 Pharmacology

Selumetinib is a non-ATP-competitive mitogen-activated protein kinase kinase 1 and 2 (MEK1 and MEK2) inhibitor. By selectively targeting MEK1 and MEK2, selumetinib is able to inhibit oncogenic downstream effects of the Raf-MEK-ERK signaling pathway, which is often overactive in certain types of cancer. Indeed, a study investigating the effects of selumetinib in children with NF-1 found that treatment with the anti-neoplastic resulted in reduced tumor size. Decreases in tumor-associated pain and improvements in overall function were also subjectively reported. Selumetinib has minimal off-target activity, contributing to its impressive safety profile.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
SELUMETINIB
5.2.2 FDA UNII
6UH91I579U
5.2.3 Pharmacological Classes
Mitogen-Activated Protein Kinase Kinase 1 Inhibitors [MoA]; Mitogen-Activated Protein Kinase Kinase 2 Inhibitors [MoA]; Kinase Inhibitor [EPC]
5.3 ATC Code

L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EE - Mitogen-activated protein kinase (mek) inhibitors

L01EE04 - Selumetinib


5.4 Absorption, Distribution and Excretion

Absorption

Based on several studies investigating selumetinib at various doses in both pediatric and adult populations, the Tmax generally ranges between 1- 1.5 hours. In healthy adults, the mean absolute oral bioavailability was reported to be 62%. Selumetinib should be administered on an empty stomach since food significantly decreases serum concentrations of the drug.


Route of Elimination

Approximately 59% of selumetinib is eliminated in the feces, while 33% is eliminated in the urine.


Volume of Distribution

The mean apparent volume of distribution of selumetinib at steady state in pediatric patients ranged from 78 L to 171 L. A study in healthy adult males found a mean apparent volume of distribution of 146 L. Another study observing the pharmacokinetic effects of various selumetinib doses and regimens in select Japanese patients found that the apparent volume of distribution values at steady-state ranged from 73.2 - 148.1 L.


Clearance

The clearance of selumetinib in pediatric patients is 8.8 L/hr. A study in healthy adult males found a clearance value of 15.7 L/hr. Another study observing the pharmacokinetic effects of various selumetinib doses and regimens in select Japanese patients found clearance values that ranged from 9.2 - 15.9 L/hr.


5.5 Metabolism/Metabolites

Selumetinib is heavily metabolized in the liver and the proposed metabolic pathway is as follows: Hydrolysis of selumetinibs amide functional group produces M15 (AZ13326637), which contains a carboxylic acid. Elimination of the ethanediol moiety from the parent compound results in the formation of the primary amide M14 (AZ12791138) metabolite. Amide hydrolysis transforms M14 into M15, glucuronidation and further oxidation of M14 leads to M2, M6 and M1, and N-demethylation of M14 produces M12. The amide glucuronide (M2) is thought to be the major circulating metabolite. Demethylation of selumetinib produces the pharmacologically active M8 (AZ12442942), and further oxidation of M8 leads to M11. Glucuronidation of M8 produces M3 or M5, and elimination of the ethanediol moiety from M8 results in a primary amide, producing M12. Although the N-demethylated metabolite (M8) accounts for <10% of the circulating metabolites, it is responsible for approximately 21-35% of any observed pharmacological activity. Ribose conjugation transforms M12 into M9, while oxidation of M12 leads to M10 and M13 metabolites. Glucuronidation of M10 produces M1. Direct glucuronidation of selumetinib produces M4 or M7, which can both eventually transform into M3 and M5 metabolites.


5.6 Biological Half-Life

Selumetinib is characterized by a short half-life. The elimination half-life associated with a dose of 25 mg/m2 in pediatric patients is 6.2 hours. In a study observing the pharmacokinetic effects of various selumetinib regimens in select Japanese patients, the half-life ranged from 9.2- 10.6 hours. In other studies where selumetinib 75 mg is administered twice daily, the half-life is reported to be approximately 13 hours.


5.7 Mechanism of Action

The Ras-Raf-MEK-ERK signaling cascade is known to be activated in several types of cancer, and regulates the transcription of proteins involved in apoptosis. In addition, studies have shown that mutations of the Raf component of the pathway can contribute to chemotherapy drug resistance. Ras as well as several kinases and phosphatases are responsible for regulating the Raf-MEK-ERK pathway. Often in cancers, Ras (a G-protein coupled receptor) is deregulated, allowing downstream signalling to proceed unchecked. Through several complex steps, Raf phosphorylates and activates MEK, which then phosphorylates and activates ERK. ERK is then able to exert its effects on several downstream targets. As such, therapies inhibiting upstream components of this pathway have become attractive targets for cancer treatment. Selumetinib exerts its effects by selectively inhibiting MEK1 and MEK2 which can effectively blunt the pleiotropic effects of the Ras-Raf-MEK-ERK cascade. By inhibiting this oncogenic pathway, selumetinib reduces cell proliferation, and promotes pro-apoptotic signal transduction.


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41492

Submission : 2025-03-31

Status : Active

Type : II

CCSB Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

SELUMETINIB SULFATE

NDC Package Code : 52076-6278

Start Marketing Date : 2023-07-10

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

CCSB Company Banner

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

SELUMETINIB SULFATE

NDC Package Code : 54864-874

Start Marketing Date : 2020-04-14

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

Selumetinib

About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast...

Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast Asia to receive FDA approval for synthetic and biotech APIs, CCSB has a proven track record of commercializing Statin, Immunosuppressant, Muscle Relaxant, and ACE Inhibitor APIs, all with complete DMF or COS. For years, CCSB has partnered with leading brand and generic drug companies to develop and produce APIs and advanced intermediates, focusing on specialty APIs crafted through a sophisticated fusion of fermentation and synthesis technologies in Taiwan.
CCSB Company Banner

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Selumetinib

About the Company : Founded in 1986, Kekule has developed from a manufacturer of few molecules to a preferred vendor for many complex molecules requiring multistage synthesis. Working with customers a...

Founded in 1986, Kekule has developed from a manufacturer of few molecules to a preferred vendor for many complex molecules requiring multistage synthesis. Working with customers across the world, Kekule has always leveraged its strengths in basic chemistry as well as chemical engineering to deliver high quality APIs and Intermediates in time and at competitive prices. Our value based approach to business has been a foundation for a mutually beneficial long term relationship with our customers. Our employees, technology and infrastructure match the highest international standards.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733250600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32512200812DT. 28.10.2024 SELUMETINIB","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"COLUMBUS, GA","customer":"N\/A","customerCountry":"UNITED STATES","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"168","totalValueFC":"16526.4","currency":"USD","unitRateINR":14042.290000000001,"date":"04-Dec-2024","totalValueINR":"1404229","totalValueInUsd":"16526.4","indian_port":"Dahez-SEZ","hs_no":"29332990","bill_no":"6156141","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724351400,"product":"SELUMETINIB SULFATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"UBERONE LLC","supplierCountry":"UNITED STATES","foreign_port":"BEIJING","customer":"MSN LABORATORIES","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"17000","totalValueFC":"8598.4","currency":"USD","unitRateINR":"1442450","date":"23-Aug-2024","totalValueINR":"721225","totalValueInUsd":"8598.4","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"5197893","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"7001 CORPORATE DR STE100 HOUSTON77306SDNF US","customerAddress":"MSN HOUSE, PLOT NO. C-24,"}]
23-Aug-2024
04-Dec-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Koselugo (selumetinib) blocks MEK1/2, which are involved in stimulating cells to grow. It is approved for the treatment of symptomatic, inoperable PNs in aged 2 years and above.


Lead Product(s): Selumetinib

Therapeutic Area: Oncology Brand Name: Koselugo

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 11, 2024

blank

01

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Koselugo (selumetinib) blocks MEK1/2, which are involved in stimulating cells to grow. It is approved for the treatment of symptomatic, inoperable PNs in aged 2 years and above.

Product Name : Koselugo

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

December 11, 2024

blank

Details:

Koselugo (selumetinib) blocks MEK1 and MEK2, which are involved in stimulating cells to grow. It is the first and only approved therapy by China’s NMPA for the treatment of symptomatic, inoperable PNs in paediatric patients with NF1 aged three years and above.


Lead Product(s): Selumetinib

Therapeutic Area: Oncology Brand Name: Koselugo

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 05, 2023

blank

02

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Details : Koselugo (selumetinib) blocks MEK1 and MEK2, which are involved in stimulating cells to grow. It is the first and only approved therapy by China’s NMPA for the treatment of symptomatic, inoperable PNs in paediatric patients with NF1 aged three years an...

Product Name : Koselugo

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

August 05, 2023

blank

Details:

Koselugo (selumetinib) has been approved in Japan for treatment of paediatric patients three years of age and older with plexiform neurofibromas in neurofibromatosis type 1 with clinical symptoms cannot be completely removed by surgery without risk of substantial morbidity.


Lead Product(s): Selumetinib

Therapeutic Area: Oncology Brand Name: Koselugo

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 27, 2022

blank

03

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Details : Koselugo (selumetinib) has been approved in Japan for treatment of paediatric patients three years of age and older with plexiform neurofibromas in neurofibromatosis type 1 with clinical symptoms cannot be completely removed by surgery without risk of su...

Product Name : Koselugo

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

September 27, 2022

blank

Details:

Recommendation based on the results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored SPRINT Stratum 1 Phase II trial, which showed selumetinib reduced tumour volume in children.


Lead Product(s): Selumetinib

Therapeutic Area: Oncology Brand Name: Koselugo

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 26, 2021

blank

04

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Details : Recommendation based on the results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored SPRINT Stratum 1 Phase II trial, which showed selumetinib reduced tumour volume in children.

Product Name : Koselugo

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

April 26, 2021

blank

Details:

In the SPRINT trial, selumetinib was shown to reduce the size of these tumours in children. Phase I/II SPRINT Stratum 1 trial showed an overall response rate of 66% in paediatric patients with NF1 PN when treated with selumetinib as a twice-daily oral monotherapy.


Lead Product(s): Selumetinib

Therapeutic Area: Oncology Brand Name: Koselugo

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 30, 2020

blank

05

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Details : In the SPRINT trial, selumetinib was shown to reduce the size of these tumours in children. Phase I/II SPRINT Stratum 1 trial showed an overall response rate of 66% in paediatric patients with NF1 PN when treated with selumetinib as a twice-daily oral mo...

Product Name : Koselugo

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

June 30, 2020

blank

Details:

The approval was based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase II SPRINT Stratum 1 trial.


Lead Product(s): Selumetinib

Therapeutic Area: Oncology Brand Name: Koselugo

Study Phase: Approved FDFProduct Type: Cytotoxic Drug

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 13, 2020

blank

06

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Details : The approval was based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase II SPRINT Stratum 1 trial.

Product Name : Koselugo

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

April 13, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Selumetinib

Brand Name : Koselugo

Dosage Form : Caps

Dosage Strength : 10mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Selumetinib

Brand Name : Koselugo

Dosage Form : Caps

Dosage Strength : 25mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Selumetinib

Brand Name : Koselugo

Dosage Form :

Dosage Strength :

Packaging : 60

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Selumetinib

Brand Name : Koselugo

Dosage Form :

Dosage Strength :

Packaging : 60

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

05

AstraZeneca

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

SELUMETINIB SULFATE

Brand Name : KOSELUGO

Dosage Form : CAPSULE;ORAL

Dosage Strength : EQ 10MG BASE

Packaging :

Approval Date : 2020-04-10

Application Number : 213756

Regulatory Info : RX

Registration Country : USA

blank

06

AstraZeneca

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

AstraZeneca

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

SELUMETINIB SULFATE

Brand Name : KOSELUGO

Dosage Form : CAPSULE;ORAL

Dosage Strength : EQ 25MG BASE

Packaging :

Approval Date : 2020-04-10

Application Number : 213756

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 606143-52-6 / Selumetinib API manufacturers, exporters & distributors?

Selumetinib manufacturers, exporters & distributors 1

92

PharmaCompass offers a list of Selumetinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Selumetinib manufacturer or Selumetinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Selumetinib manufacturer or Selumetinib supplier.

PharmaCompass also assists you with knowing the Selumetinib API Price utilized in the formulation of products. Selumetinib API Price is not always fixed or binding as the Selumetinib Price is obtained through a variety of data sources. The Selumetinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Selumetinib

Synonyms

606143-52-6, Azd6244, Arry-142886, Azd 6244, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-n-(2-hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide, Azd-6244

Cas Number

606143-52-6

Unique Ingredient Identifier (UNII)

6UH91I579U

About Selumetinib

Selumetinib is an orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.

Selumetinib Manufacturers

A Selumetinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Selumetinib, including repackagers and relabelers. The FDA regulates Selumetinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Selumetinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Selumetinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Selumetinib Suppliers

A Selumetinib supplier is an individual or a company that provides Selumetinib active pharmaceutical ingredient (API) or Selumetinib finished formulations upon request. The Selumetinib suppliers may include Selumetinib API manufacturers, exporters, distributors and traders.

click here to find a list of Selumetinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Selumetinib USDMF

A Selumetinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Selumetinib active pharmaceutical ingredient (API) in detail. Different forms of Selumetinib DMFs exist exist since differing nations have different regulations, such as Selumetinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Selumetinib DMF submitted to regulatory agencies in the US is known as a USDMF. Selumetinib USDMF includes data on Selumetinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Selumetinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Selumetinib suppliers with USDMF on PharmaCompass.

Selumetinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Selumetinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Selumetinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Selumetinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Selumetinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Selumetinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Selumetinib suppliers with NDC on PharmaCompass.

Selumetinib GMP

Selumetinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Selumetinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Selumetinib GMP manufacturer or Selumetinib GMP API supplier for your needs.

Selumetinib CoA

A Selumetinib CoA (Certificate of Analysis) is a formal document that attests to Selumetinib's compliance with Selumetinib specifications and serves as a tool for batch-level quality control.

Selumetinib CoA mostly includes findings from lab analyses of a specific batch. For each Selumetinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Selumetinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Selumetinib EP), Selumetinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Selumetinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty